Incretin Atlas › Trials › BGM0504 phase 2 (China, obesity)
BGM0504 phase 2 (China, obesity)
BGM0504 · obesity
Design
- Molecule(s)
- BGM0504
- Population
- obesity
- Phase
- 2
- Duration
- 24 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BGM0504 5 mg | obesity china | 24 | — | — | —−10.7 % vs +0.1 % estimand not specified | — | — | — | — | — | — | — | verified |
| BGM0504 10 mg | obesity china | 24 | — | — | —−16.1 % vs +0.1 % estimand not specified | — | — | — | — | — | — | — | verified |
| BGM0504 15 mg | obesity china | 24 | — | — | —−18.3 % vs +0.1 % estimand not specified | — | — | — | — | — | — | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- BGM0504 5 mg: The abstract reports that no adverse event led to withdrawal from the trial; discontinuation of the study drug is not reported.
- BGM0504 10 mg: The abstract reports that no adverse event led to withdrawal from the trial; discontinuation of the study drug is not reported.
- BGM0504 15 mg: The abstract reports that no adverse event led to withdrawal from the trial; discontinuation of the study drug is not reported.
Verbatim quotes from the source (3)
- BGM0504 5 mg · weight_unsp · Abstract
Mean percentage changes in body weight from baseline to week 24 were -10.68%
- BGM0504 10 mg · weight_unsp · Abstract
Mean percentage changes in body weight from baseline to week 24 were -10.68%
- BGM0504 15 mg · weight_unsp · Abstract
Mean percentage changes in body weight from baseline to week 24 were -10.68%
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: BGM0504 phase 2 (China, obesity). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/bgm0504-phase-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.